

c.) Amendments to the Claims

Claim 1. (Cancelled)

2. (Currently Amended) A compound according to claim 1, represented by formula (I):

R¹-A-R² (I)

wherein

R¹ represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a hydrogen atom;

R² represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and

A is represented by the general formula (Ia); formulae (Ia), (Ib) or (Ic):

- (X ¹) n	- (X ²) n	- (X ³) n	- (Ala) n	- (X ⁵) n	-
(X ⁶) n	- (X ⁷) n	- (X ⁸) n	- (X ⁹) n	- Val	-
Gln	- Lys	Arg	- Arg	- Ile	-
Tyr	- Asp	- Ile	- Thr	- Asn	-
Val	- (Leu) n	- (Glu) n	- (Gly) n	- (Ile)	-
(X ²⁶) n	- (X ²⁷) n	- (X ²⁸) n	- (X ²⁹) n	-	

(Ia, SEQ ID NO:25)

(wherein "n's" in individual amino acid residues are the same or different, and independently represent 0 or 1; X¹, X⁸, X²⁷ and X²⁸ are the same or different, independently representing Leu or Ile; X² represents Asn or Lys; X³ represents Trp, Lys, Leu,

Ala or Glu; X⁵ represents Ala or Ser; X⁶ represents Glu, Asp or Asn; X⁷ represents Val, Thr or Arg; X⁹ represents Lys, Asp, Ala or His; X²⁶ represents Gln, His, Gly, Asp or Asn; and X²⁹ represents Ala, Arg, Lys or Glu), or by the general formula (Ib);

- (Y ¹) m	- (Y ²) m	- (Y ³) m	- (Gln) m	- (Y ⁵) m	-
(Y ⁶) m	- (Asp) m	- (Gln) m	- (Y ⁹) m	- (Asn) m	-
Ile	- Arg	- Arg	- Arg	- Val	-
Tyr	- Asp	- Ala	- Leu	- Asn	-
Val	- Leu	- Met	- Ala	- Y ²⁵	-
(Asn) m	- (Y ²⁷) m	- (Ile) m	- (Ser) m	-	

(Ib, SEQ ID NO:26)

(wherein "m's" in individual amino acid residues are the same or different, and independently represent 0 or 1; Y¹ represents Asn, Thr, Ala or Tyr; Y² represents Glu or Asp; Y³ represents Ser or Asn; Y⁵ represents Ala or Asn; Y⁶ represents Tyr or Cys; Y⁹ represents Lys or Glu; Y²⁵ represents Met or Ile; and Y²⁷ represents Ile or Val), or by the general formula (Ic);

- (Z ¹) p	- (Z ²) p	- (Z ³) p	- (Z ⁴) p	- (Z ⁵) p	-
(Z ⁶) p	- (Z ⁷) p	- (Z ⁸) p	- (Z ⁹) p	- (Z ¹⁰) p	-
(Z ¹¹) p	- (Z ¹²) p	- (Z ¹³) p	- (Z ¹⁴) p	- (Z ¹⁵) p	-
(Z ¹⁶) p	- (Z ¹⁷) p	- (Z ¹⁸) p	- (Z ¹⁹) p	- (Z ²⁰) p	-
(Z ²¹) p	- (Z ²²) p	- (Z ²³) p	- (Z ²⁴) p	- (Z ²⁵) p	-
Arg	- Z ²⁷	- Z ²⁸	- Z ²⁹	- Ser	-
Leu	- Z ³²	- Leu	- Z ³⁴	- Thr	-
Z ³⁶	- Z ³⁷	- Phe	- Z ³⁹	- Z ⁴⁰	-
Leu	-				

(Ic, SEQ ID NO:27)


(wherein "p's" in individual amino acid residues are the same or different, and independently represent 0 or 1; Z¹ represents Ala, Phe or Pro; Z² represents Arg, Lys, or

Gln; Z³, Z¹⁵ and Z²¹ are the same or different, representing independently represent Gly or Pro; Z⁴ represents Arg, Lys, Met or Pro; Z⁵ represents Gly, Cys, Ala or Gln; Z⁶ represents Ala, Arg or Glu; Z⁷ represents Ala, Ile or Gln; Z⁸ represents Ala, Gly or Arg, Z⁹ represents Leu, Val or Pro; Z¹⁰ represents Asp, Arg or Gln; Z¹¹ represents Gly, Ser, Ala or Pro; Z¹² represents Leu or Pro; Z¹³ represents Asp, His or Pro; Z¹⁴ represents Ser or Pro; Z¹⁶ represents Gln or Lys; Z¹⁷ represents Gly, Thr or Leu; Z¹⁸ represents Gly, Pro or Val; Z¹⁹ represents Gly or Lys; Z²⁰ represents Ala or Ser; Z²² represents Gly or Ser; Z²³ represents Gly, Glu or Thr; Z²⁴ represents Arg, Lys, Ser or Pro; Z²⁵ represents Ser or Thr; Z²⁷ represents His or Tyr; Z²⁸ represents Asp or Glu; Z²⁹ and Z³⁶ are the same or different, representing independently represent Lys or Thr; Z³² represents Gly or Asn; Z³⁴ represents Leu or Thr; Z³⁷ represents Arg or Lys; Z³⁹ represents Ile, Leu or Val; and Z⁴⁰ represents Glu, Gln, Ser or Tyr);

or a pharmaceutically acceptable salt thereof

with the proviso that A is not an intact peptide that which is a member of E2F family or DP family.

3. (Currently Amended) A pharmaceutical composition comprising:
a pharmaceutically pure compound represented by the general formula (I);



(wherein

R¹ represents substituted or unsubstituted alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted alkoxy carbonyl, substituted or unsubstituted aryloxycarbonyl, substituted or unsubstituted heteroaryloxycarbonyl or a hydrogen atom;

R² represents hydroxy, substituted or unsubstituted alkoxy, or substituted or unsubstituted amino; and

A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of each E2F family)

or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.

4. (New) A compound according to claim 2, wherein A comprises SEQ ID NO:25, or a pharmaceutically acceptable salt thereof.

5. (New) A compound according to claim 2, wherein A consists of SEQ ID NO:26, or a pharmaceutically acceptable salt thereof.

6. (New) A compound according to claim 2, wherein A consists of SEQ ID NO:27, or a pharmaceutically acceptable salt thereof.

7. (New) A compound according to claim 6, wherein A consists of:

- Ile - Arg - Arg - Arg - Val -
Tyr - Asp - Ala - Leu - Asn -
Val - Leu - Met - Ala - Met -

(SEQ ID NO:23)

or a pharmaceutically acceptable salt thereof.

8. (New) A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 7, and a pharmaceutically acceptable carrier.